← Leaderboards
Dung "zung" Thai
Remd Biotherapeutics, Inc.
$1,490,470
Attributed
$2,980,940
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $993.8K · FY2019–21$1M$750K$500K$250K$0
'19
'20
'21
Funding mix
By agency
NIH$2,980,940 · 1
By mechanism
R44$2,980,940 · 1
Top collaborators
- Samuel Klein3 shared
Others in their field
Other Emerging Leaders on “Affinity”
- Bala Raja · Luminostics, Inc.$28,624,460
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$25,726,378
- Tharick Pascoal · University Of Pittsburgh At Pittsburgh$20,465,582
- Suzanne L Baker · University Of Pittsburgh At Pittsburgh$20,465,582
- Ashlin Bolton · Broad Institute, Inc.$19,699,069
- Timothy M Willson · University Of Cape Town$13,865,323
Research focus
AffinityAffectAnimal ModelAnimalsAntibodiesAlpha CellAntidiabetic DrugsArea Under CurveArginineAwardBaseBenignBeta CellBindingBlocking AntibodiesBlood GlucoseBlood Glucose RegulationBody WeightCardiovascular SystemCell PhysiologyCellsCessation Of LifeChronicClinical Research
Grant awards (3)
Assessment of Multiple Dose Administration ofGlucagon Receptor Blocker REMD477 in Type 1 Diabetes$993,807
R44 · FY2021 · DK · contact PI
Assessment of Multiple Dose Administration ofGlucagon Receptor Blocker REMD477 in Type 1 Diabetes$993,807
R44 · FY2020 · DK · contact PI
Assessment of Multiple Dose Administration of Glucagon Receptor Blocker REMD477 in Type 1 Diabetes$993,326
R44 · FY2019 · DK · contact PI